chlordiazepoxide has been researched along with cp 154526 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Christ, D; Fitzgerald, LW; Gilligan, PJ; Hartig, P; He, L; Kalin, NH; McElroy, J; Saye, JA; Shelton, S; Shen, HS; Trainor, G; Zaczek, R | 1 |
| Arneric, SP; Bai, S; Clarke, T; Fitzgerald, L; Gilligan, PJ; Grossman, S; Hartig, P; He, L; Heman, K; Krause, C; Lelas, S; Li, YW; Marshall, A; McElroy, JF; Miller, K; Robertson, D; Saye, J; Trainor, G; Ward, K; Wong, H; Zaczek, R; Zeller, K; Zhang, G | 1 |
2 other study(ies) available for chlordiazepoxide and cp 154526
| Article | Year |
|---|---|
4-(1,3-Dimethoxyprop-2-ylamino)-2,7-dimethyl-8-(2, 4-dichlorophenyl)pyrazolo[1,5-a]-1,3,5-triazine: a potent, orally bioavailable CRF(1) receptor antagonist.
Topics: Administration, Oral; Animals; Anti-Anxiety Agents; Biological Availability; Brain; Cardiovascular System; Dogs; Female; Gastrointestinal Motility; Humans; Kidney Function Tests; Macaca mulatta; Male; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Corticotropin-Releasing Hormone; Respiratory Physiological Phenomena; Structure-Activity Relationship; Triazines | 2000 |
Synthesis and structure-activity relationships of 8-(pyrid-3-yl)pyrazolo[1,5-a]-1,3,5-triazines: potent, orally bioavailable corticotropin releasing factor receptor-1 (CRF1) antagonists.
Topics: Administration, Oral; Animals; Behavior, Animal; Biological Availability; Clinical Trials as Topic; Dogs; Inhibitory Concentration 50; Rats; Receptors, Corticotropin-Releasing Hormone; Solubility; Structure-Activity Relationship; Triazines; Water | 2009 |